文献速递泌尿男性生殖肿瘤

间歇性舒尼替尼治疗初治转移性肾细胞癌的II期研究

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.
PubMed 文献 · J Clin Oncol · 2017-01-23

这项II期研究评估了间歇性舒尼替尼给药在初治透明细胞型转移性肾细胞癌患者中的可行性和临床结局。37例入组患者中20例符合间歇治疗条件且全部进入间歇期,前四周期客观缓解率为46%,中位无进展生存期22.4个月,中位总生存期34.8个月。作者认为周期性延长舒尼替尼治疗间歇是可行的,临床疗效似乎未受影响。

要点

  • 37例入组患者中20例符合条件并全部(100%)进入间歇治疗期。
  • 前四周期舒尼替尼治疗后客观缓解率为46%。
  • 中位无进展生存期22.4个月,中位总生存期34.8个月。

核心结论

  • 周期性延长舒尼替尼治疗间歇是可行的,临床疗效似乎未受影响。

研究设计与样本

  • II期研究,入组37例初治透明细胞型转移性肾细胞癌患者。
  • 患者接受四周期舒尼替尼(50 mg每日一次,服药4周后停药2周)。
  • 四周期后肿瘤负荷缩小≥10%的患者暂停舒尼替尼,每两周期复查再分期。
  • 肿瘤负荷增大≥10%的患者重新开始两周期舒尼替尼,肿瘤负荷缩小≥10%后再次暂停。
  • 间歇给药持续至舒尼替尼治疗期间出现实体瘤疗效评价标准定义的疾病进展或不可接受的毒性。

主要发现

  • 37例入组患者中20例符合间歇治疗条件,全部(100%)进入间歇期。
  • 不符合间歇治疗条件的原因:疾病进展(n=13)、毒性(n=1)、第4周期结束前撤回知情同意(n=3)。
  • 前四周期治疗后客观缓解率为46%。
  • 停药期间肿瘤负荷中位增量为1.6 cm(范围,-2.9至3.4 cm),对照为停药前的肿瘤负荷。
  • 多数患者呈现肿瘤负荷在服药期间缩小、停药期间增大的稳定锯齿状模式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Sunitinib is a standard initial therapy in metastatic renal cell carcinoma (mRCC), but chronic dosing requires balancing toxicity with clinical benefit. The feasibility and clinical outcome with intermittent sunitinib dosing in patients with mRCC was explored. Patients and Methods Patients with treatment-naïve, clear cell mRCC were treated with four cycles of sunitinib (50 mg once per day, 4 weeks of receiving treatment followed by 2 weeks of no treatment). Patients with a ≥ 10% reduction in tumor burden (TB) after four cycles had sunitinib held, with restaging scans performed every two cycles. Sunitinib was reinitiated for two cycles in those patients with an increase in TB by ≥ 10%, and again held with ≥ 10% TB reduction. This intermittent sunitinib dosing continued until Response Evaluation Criteria in Solid Tumors-defined disease progression while receiving sunitinib, or unacceptable toxicity occurred. The primary objective was feasibility, defined as the proportion of eligible patients who underwent intermittent therapy. Results Of 37 patients enrolled, 20 were eligible for intermittent therapy and all patients (100%) entered the intermittent phase. Patients were not eligible for intermittent sunitinib because of progressive disease (n = 13), toxicity (n = 1), or consent withdrawal (n = 3) before the end of cycle 4. The objective response rate was 46% after the first four cycles of therapy. The median increase in TB during the periods off sunitinib was 1.6 cm (range, -2.9 to 3.4 cm) compared with the TB immediately before stopping sunitinib. Most patients exhibited a stable sawtooth pattern of TB reduction while receiving sunitinib and TB increase while not receiving sunitinib. Median progression-free survival to date is 22.4 months (95% CI, 5.4 to 37.6 months) and median overall survival is 34.8 months (95% CI, 14.8 months to not applicable). Conclusion Periodic extended sunitinib treatment breaks are feasible and clinical efficacy does not seem to be compromised.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ornstein MC, Wood LS, Elson P, et al. A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2017. PMID: 28113029. doi:10.1200/JCO.2016.71.1184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。